28 September 2022: Clinical Research
Factors Predictive of Varicella Zoster Virus Encephalitis/Meningitis: A Single-Center, Retrospective Study
Yanrong Yuan ABCE , Jun Wang BCF , Yan Zhang BC , Huili Liu BC , Yongxing Yan ACDFG*DOI: 10.12659/MSM.938057
Med Sci Monit 2022; 28:e938057
Table 2 Clinical characteristics of patients in 2 groups.
| Favorable outcome group (18) | Unfavorable outcome group (21) | |
|---|---|---|
| Site of herpes zoster (n) | ||
| Head and face | 13 | 19 |
| Neck | 1 | 1 |
| Chest and back | 4 | 1 |
| Waist | 1 | 0 |
| Limbs | 0 | 1 |
| Clinical manifestations (n) | ||
| Headache | 13 | 14 |
| Fever (temperature >38°C) | 6 | 15* |
| Cognitive change | 0 | 4 |
| RHS | 1 | 6 |
| Seizure | 0 | 1 |
| Disturbance of consciousness | 0 | 3 |
| Time interval from herpes zoster to onset of CNS symptoms [median (Q1–Q3)] (days) | 3.5 (2.8–5.3) | 2 (1–5) |
| Time interval from onset of CNS symptoms to initiation of antiviral therapy [median (Q1–Q3)] (days) | 1 (1–2) | 4 (2–6)** |
| Hospital stay (mean±SD) (days) | 17.6±3.6 | 18.7±8.4 |
| Duration of intravenous antiviral therapy (mean±SD)(days) | 15.9±3.6 | 15.7±5.7 |
| Glucocorticoids therapy (n) | 12 | 16 |
| * ** | ||